Tenax Therapeutics Inc
TENX13.100USD
+0.280+2.18%
收盤 12/19, 16:00（美東）報價延遲15分鐘
77.38M總市值
虧損本益比TTM
關於 Tenax Therapeutics Inc 公司
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Tenax Therapeutics Inc簡介
公司代碼TENX
公司名稱Tenax Therapeutics Inc
上市日期Oct 28, 1993
CEOGiordano (Christopher T)
員工數量4
證券類型Ordinary Share
年結日Oct 28
公司地址101 Glen Lennox Drive
城市CHAPEL HILL
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編27517
電話19198552100
網址http://www.tenaxthera.com/
公司代碼TENX
上市日期Oct 28, 1993
CEOGiordano (Christopher T)
Tenax Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
7.65K
+188.39%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Robyn M. Hunter
Ms. Robyn M. Hunter
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
7.65K
+188.39%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月28日 週五
更新時間: 11月28日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Ikarian Capital LLC
15.50%
Janus Henderson Investors
9.99%
VR Adviser, LLC
7.01%
Invus Public Equities Advisors, LLC
6.84%
RTW Investments L.P.
6.06%
其他
54.60%
持股股東
持股股東
佔比
Ikarian Capital LLC
15.50%
Janus Henderson Investors
9.99%
VR Adviser, LLC
7.01%
Invus Public Equities Advisors, LLC
6.84%
RTW Investments L.P.
6.06%
其他
54.60%
股東類型
持股股東
佔比
Hedge Fund
44.91%
Investment Advisor/Hedge Fund
27.27%
Venture Capital
10.35%
Investment Advisor
9.67%
Research Firm
2.99%
Individual Investor
0.34%
其他
4.47%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
56
4.15M
90.85%
+1.27M
2025Q2
58
2.98M
71.83%
+986.76K
2025Q1
58
2.74M
66.20%
+755.49K
2024Q4
56
1.98M
58.13%
+213.72K
2024Q3
58
1.98M
66.48%
+633.55K
2024Q2
48
161.28K
18.23%
+129.16K
2024Q1
48
149.68K
17.63%
+121.80K
2023Q4
43
26.36K
16.08%
+6.23K
2023Q3
45
17.13K
13.16%
+882.00
2023Q2
48
14.32K
12.38%
-2.77K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Ikarian Capital LLC
967.60K
21.21%
+967.60K
--
Sep 30, 2025
Janus Henderson Investors
166.67K
3.65%
--
--
Jun 30, 2025
VR Adviser, LLC
98.56K
2.16%
-109.77K
-52.69%
Jun 30, 2025
RTW Investments L.P.
378.35K
8.29%
--
--
Jun 30, 2025
Dellora Investments LP
351.07K
7.69%
--
--
Mar 05, 2025
BVF Partners L.P.
339.55K
7.44%
--
--
Jun 30, 2025
Millennium Management LLC
233.71K
5.12%
+207.09K
+777.77%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
DFA Dimensional US Sustainability Core 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Jan 04, 2023
Merger
20→1
Jan 04, 2023
Merger
20→1
公告日期
類型
比率
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Jan 04, 2023
Merger
20→1
Jan 04, 2023
Merger
20→1
Jan 04, 2023
Merger
20→1
Jan 04, 2023
Merger
20→1
常見問題
Tenax Therapeutics Inc的前五大股東是誰？
Tenax Therapeutics Inc的前五大股東如下：
Ikarian Capital LLC持有股份：967.60K佔總股份比例：21.21%。
Janus Henderson Investors持有股份：166.67K佔總股份比例：3.65%。
VR Adviser, LLC持有股份：98.56K佔總股份比例：2.16%。
RTW Investments L.P.持有股份：378.35K佔總股份比例：8.29%。
Dellora Investments LP持有股份：351.07K佔總股份比例：7.69%。
Ikarian Capital LLC持有股份：967.60K佔總股份比例：21.21%。
Janus Henderson Investors持有股份：166.67K佔總股份比例：3.65%。
VR Adviser, LLC持有股份：98.56K佔總股份比例：2.16%。
RTW Investments L.P.持有股份：378.35K佔總股份比例：8.29%。
Dellora Investments LP持有股份：351.07K佔總股份比例：7.69%。
Tenax Therapeutics Inc的前三大股東類型是什麼？
Tenax Therapeutics Inc 的前三大股東類型分別是：
Ikarian Capital LLC
Janus Henderson Investors
VR Adviser, LLC
Ikarian Capital LLC
Janus Henderson Investors
VR Adviser, LLC
有多少機構持有Tenax Therapeutics Inc(TENX)的股份？
截至2025Q3，共有56家機構持有Tenax Therapeutics Inc的股份，合計持有的股份價值約為4.15M，占公司總股份的90.85% 。與2025Q2相比，機構持股有所增加，增幅為19.03%。
哪個業務部門對Tenax Therapeutics Inc的收入貢獻最大？
在--，--業務部門對Tenax Therapeutics Inc的收入貢獻最大，創收--，占總收入的--% 。
